Tempus PurIST℠ Pancreatic Cancer Test
Pancreatic cancer is the third leading cause of cancer-related deaths worldwide, with pancreatic ductal adenocarcinoma (PDAC) as the predominant histologic subtype. Despite advances in imaging and chemotherapy, effective biomarkers for guiding treatment remain limited.
The Tempus PurIST℠ (Purity Independent Subtyping of Tumors) test classifies patients with unresectable stage III or stage IV PDAC into molecular subtypes using RNA sequencing with an AI-driven algorithm. The test identifies two clinically relevant PDAC subtypes:
- Classical subtype – associated with better prognosis and improved median overall survival, particularly when treated with first-line FOLFIRINOX.
- Basal subtype – associated with more aggressive biology, poorer prognosis, and reduced benefit from FOLFIRINOX.
This classification provides actionable insights to personalize therapy and optimize outcomes for patients with advanced pancreatic cancer.
- Enables tumor subtyping to guide therapy selection
- Provides prognostic information to predict disease aggressiveness and survival
- Assists in tailoring first-line chemotherapy strategies, especially FOLFIRINOX
Reported as the probability of predicted molecular subtype (Classical vs. Basal).
Classical subtype: associated with better response and survival outcomes.
Basal subtype: associated with poorer outcomes, prompting consideration of alternative therapies.
Not applicable (reported as subtype probability)
Whole blood, EDTA.
Stability
- Ambient: 48 hours
- Refrigerated: 7 days
- Frozen: 30 days
- Clin Cancer Res. 2020;26(1):82-92. [PMID: 31754050]
- J Mol Diagn. 2024 Nov;26(11):962-970. [PMID: 39181325]
- J Gastroenterol Hepatol. 2016 Jun;31(6):1160-7. [PMID: 26644397]
- Clin Gastroenterol Hepatol. 2023 Jul;21(7):1802-1809.e6. [PMID: 36967102]